Association between COVID-19 Vaccine Side Effects and Body Mass Index in Spain

Iguacel, Isabel (Universidad de Zaragoza) ; Luna Maldonado, Aurelio ; Luna Ruiz-Cabello, Aurelio ; Casaus, Marta ; Moreno, Luis Alberto (Universidad de Zaragoza) ; Martínez-Jarreta, Begoña (Universidad de Zaragoza)

Resumen: COVID-19 vaccines have shown high efficacy, with most side effects being mild-moderate and more frequently reported by females and people at younger ages. Since no studies have assessed the impact that weight status could have on the reported adverse reactions, we aim to study the association between weight status and reported side effects. We included data on 2136 adults from an online survey conducted from 6 May to 9 June 2021. The questionnaire was filled in by participants over Google forms. Generalized Linear Mixed Models were used. A higher risk of presenting fever \u226538\u00b0, vomiting, diarrhea and chills was found in those with a non-overweight status compared to those overweight after adjusting for age, sex, education, medication to preventrelieve post-vaccination effects and vaccine administered. When adjusting, most of the significant effects, in the association between side effects of the COVID-19 vaccine and weight status, did not remain significant. In conclusion, a non-overweight status was associated with a higher risk of presenting fever \u226538\u00b0, vomiting, diarrhea and chills compared to those overweight. Nevertheless, most of the reported side effects to COVID-19 vaccine were not associated with a higher risk of presenting more adverse effects, and individual differences were determined by sex and age.

Idioma: Inglés

DOI: 10.3390/vaccines9111321

Año: 2021

Publicado en: Vaccines 9, 11 (2021), 1321 [12 pp.]
ISSN: 2076-393X

Factor impacto JCR: 4.961 (2021)

Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 59 / 139 = 0.424 (2021) - Q2 - T2
Categ. JCR: IMMUNOLOGY rank: 77 / 162 = 0.475 (2021) - Q2 - T2

Factor impacto CITESCORE: 4.5 - Medicine (Q2) - Pharmacology, Toxicology and Pharmaceutics (Q2) - Immunology and Microbiology (Q3)

Factor impacto SCIMAGO: 1.004 - Drug Discovery (Q1) - Pharmacology (Q1) - Infectious Diseases (Q1) - Immunology (Q1)

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Área Enfermería (Dpto. Fisiatría y Enfermería)
Área (Departamento): Área Medicina Legal y Forense (Dpto. Farmac.Fisiol.y Med.L.F.)